EUVIMEDEUVIMED entdecken
Crossref

QbD enabled RP - HPLC method optimization and validation for estimation of levetiracetam in bulk and pharmaceutical formulation

{"name":"Yamini Marathe","email":"yaminimarathe76@gmail.com","affiliation":", {"name":"Aejaz Ahmed","email":"yaminimarathe76@gmail.com","affiliation":"De, {"name":"Gulam J. Khan","email":"yaminimarathe76@gmail.com","affiliation":", {"name":"Alamsara Qureshi","email":"yaminimarathe76@gmail.com","affiliation":"

Future Journal of Pharmaceuticals and Health Sciences · 10.04.2026 · 6 (2) · 38-50

DOI: 10.26452/fjphs.v6i2.557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Journal of Pharmaceuticals and Health Sciences, online erschienen am 10.04.2026. Verfasst von {"name":"Yamini Marathe","email":"yaminimarathe76@gmail.com","affiliation":" und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Levetiracetam is an antiepileptic medication commonly utilized for controlling and treating seizure disorders. In this study, a straightforward, fast, reliable, and highly accurate RP - HPLC technique was successfully designed and validated for routine asses sment in both bulk substances and solid dosage formulations. The optimization of the analytical procedure was performed using Design of Experiments (DoE) along with ANOVA to determine the key variables influencing chromatographic efficiency. The proportion of methanol in the mobile phase and the flow rate were chosen as independent parameters, whereas retention time and peak response were treated as dependent outcomes. Effective chromatographic resolution was accomplished using a C18 column ( 250 mm × 4.6 mm, 5 μm particle size) with a mobile phase composed of methanol and water in a 70:30 (v/v) ratio at a flow rate of 0.9 mL/min. Detection was carried out at a wavelength of 206 nm. The method validation was conducted in accordance with ICH recommendations an d exhibited excellent linearity across a concentration interval of 20 – 100 μg/mL, with a correlation coefficient of 0.9992. Accuracy evaluation at 80%, 100%, and 120% levels demonstrated acceptable recovery rates, while precision studies (both intra - day and inter - day) showed %RSD values below 2%, indicating strong consistency. The limits of detection (LOD) and quantification (LOQ) were determined to be 0.0044 μg/mL and 0.01347 μg/mL, respectively. Analysis of commercial formulations aligned well with labeled claims (100 ± 1%), confirming the method’s reliability. System suitability criteria, including peak symmetry and %RSD (

Zitieren

APA

Marathe","email":"yaminimarathe76@gmail.com","affiliation":", N., Ahmed","email":"yaminimarathe76@gmail.com","affiliation":"De, N., Khan","email":"yaminimarathe76@gmail.com","affiliation":", N. J., & Qureshi","email":"yaminimarathe76@gmail.com","affiliation":", N. (2026). QbD enabled RP - HPLC method optimization and validation for estimation of levetiracetam in bulk and pharmaceutical formulation. Future Journal of Pharmaceuticals and Health Sciences, 6(2), 38-50. https://doi.org/10.26452/fjphs.v6i2.557

Vancouver

Marathe","email":"yaminimarathe76@gmail.com","affiliation":" N, Ahmed","email":"yaminimarathe76@gmail.com","affiliation":"De N, Khan","email":"yaminimarathe76@gmail.com","affiliation":" NJ, Qureshi","email":"yaminimarathe76@gmail.com","affiliation":" N. QbD enabled RP - HPLC method optimization and validation for estimation of levetiracetam in bulk and pharmaceutical formulation. Future Journal of Pharmaceuticals and Health Sciences. 2026;6(2):38-50. doi:10.26452/fjphs.v6i2.557

BibTeX
@article{Maratheemailyaminimarathegmailcomaffiliation2026,
  author = {Marathe","email":"yaminimarathe76@gmail.com","affiliation":", "name":"Yamini and Ahmed","email":"yaminimarathe76@gmail.com","affiliation":"De, "name":"Aejaz and Khan","email":"yaminimarathe76@gmail.com","affiliation":", "name":"Gulam J. and Qureshi","email":"yaminimarathe76@gmail.com","affiliation":", "name":"Alamsara},
  title = {QbD enabled RP - HPLC method optimization and validation for estimation of levetiracetam in bulk and pharmaceutical formulation},
  journal = {Future Journal of Pharmaceuticals and Health Sciences},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {38--50},
  doi = {10.26452/fjphs.v6i2.557}
}
Kostenlos starten →